Clinical Read2026-06-02

Izalontamab brengitecan - (PANKU-Breast02)

Name: Izalontamab brengitecan - (PANKU-Breast02)
Start: 2026-06-02

Bristol-Myers Squibb CompanyBMY

Indication: Unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC)
Stage: phase3
Event: Phase 3